Eprosartan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Eprosartan
Eprosartan.svg
Systematic (IUPAC) name
4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
Clinical data
Trade names Teveten
AHFS/Drugs.com monograph
MedlinePlus a601237
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 15% (Eprosartan mesylate)
Metabolism not metabolized
Biological half-life 5 to 9 hours
Excretion Renal 10%, biliary 90%
Identifiers
CAS Registry Number 133040-01-4 YesY
ATC code C09CA02
PubChem CID: 5281037
IUPHAR/BPS 588
DrugBank DB00876 YesY
ChemSpider 4444504 YesY
UNII 2KH13Z0S0Y YesY
KEGG D04040 YesY
ChEBI CHEBI:4814 YesY
ChEMBL CHEMBL813 YesY
Chemical data
Formula C23H24N2O4S
Molecular mass Eprosartan mesylate: 520.625 g/mol
 YesY (what is this?)  (verify)

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed in the United States as Teveten by Abbvie, the spin-off of the pharmaceutical discovery division of Abbott Laboratories; it is marketed as Eprozar by INTAS Pharmaceuticals in India, and by Abbott Laboratories elsewhere. The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[1]

Eprosartan is sometimes paired with hydrochlorothiazide, whereupon it is marketed in the US as Teveten HCT and elsewhere as Teveten Plus.

The drug acts on the renin-angiotensin system to decrease total peripheral resistance in two ways. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[2]

See also[edit]

References[edit]

  1. ^ Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see [1], accessed 29 January 2015.
  2. ^ Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061. 

External links[edit]